Genelux
Genelux is a biopharmaceutical company that develops diagnostic and therapeutic solutions for cancer and inflammatory diseases.
About Genelux
Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company that has developed a proprietary oncolytic virus-based technology platform and a deep pipeline of products with broad applications for cancer detection and therapy. GL-ONC1 the company’s lead oncology product candidate is an attenuated vaccinia virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1 encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. GL-ONC1 is currently under evaluation in Phase I/II human clinical trials in the United States and Europe, and additional US and European-based trials are set to begin in the near future. GL-ONC1 is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.
Company Facts
- Headquarters
- Westlake Village
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- public
- Employees
- c_00011_00050
- Funding Stage
- ipo
- Total Funding
- $129,481,268
- Last Funding Type
- post_ipo_equity
- Last Funding Date
- 2026-01-09
- Website
- genelux.com
Industries & Categories
Biopharma, Biotechnology, Health Care, Health Diagnostics
Social Links
Canonical: https://fsome.com/organization/genelux-32590 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.